Holen Sie sich die Stockscreener-App
29.59
2.92%
0.84
Handel nachbörslich:
29.59
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ENOV?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$28.75
Offen:
$28.9
24-Stunden-Volumen:
1.60M
Relative Volume:
1.10
Marktkapitalisierung:
$1.69B
Einnahmen:
$2.15B
Nettoeinkommen (Verlust:
$-809.46M
KGV:
-2.1211
EPS:
-13.95
Netto-Cashflow:
$-38.98M
1W Leistung:
+14.87%
1M Leistung:
-13.05%
6M Leistung:
-32.30%
1J Leistung:
-31.60%
1-Tages-Spanne:
$28.74
$30.31
1-Wochen-Bereich:
$26.90
$30.31
52-Wochen-Spanne:
$25.46
$49.83
Enovis Corp Stock (ENOV) Company Profile
Firmenname
Enovis Corp
Sektor
Branche
Telefon
(302) 252-9160
Adresse
2711 CENTERVILLE ROAD, WILMINGTON
Vergleichen Sie ENOV mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ENOV
Enovis Corp
|
29.59 | 1.64B | 2.15B | -809.46M | -38.98M | -13.95 |
|
ABT
Abbott Laboratories
|
129.40 | 228.03B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
102.50 | 152.09B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
378.95 | 143.98B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.91 | 117.98B | 33.54B | 4.69B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
77.68 | 45.17B | 5.69B | 1.41B | 577.90M | 6.95 |
Enovis Corp Stock (ENOV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-03 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-06-13 | Eingeleitet | JP Morgan | Neutral |
| 2024-02-13 | Eingeleitet | Stephens | Overweight |
| 2024-01-22 | Eingeleitet | UBS | Buy |
| 2024-01-03 | Eingeleitet | William Blair | Outperform |
| 2023-12-15 | Bestätigt | Needham | Buy |
| 2023-10-20 | Eingeleitet | ROTH MKM | Buy |
| 2023-06-26 | Eingeleitet | Needham | Buy |
| 2023-05-12 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-10-11 | Eingeleitet | Goldman | Buy |
| 2022-09-12 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-09-12 | Eingeleitet | Evercore ISI | Outperform |
| 2022-06-28 | Eingeleitet | Argus | Hold |
| 2022-06-27 | Fortgesetzt | Loop Capital | Buy |
| 2022-06-16 | Eingeleitet | Wells Fargo | Equal Weight |
Alle ansehen
Enovis Corp Aktie (ENOV) Neueste Nachrichten
Tandem Diabetes, Enovis, Dentsply Sirona, Centene, and Molina Healthcare Shares Are Soaring, What You Need To Know - TradingView
Tandem Diabetes, Enovis, Dentsply Sirona, Centene, and Molina Healthcare Shares Are Soaring, What You Need To Know | FinancialContent - FinancialContent
Enovis price target lowered to $58 from $70 at Canaccord - MSN
UBS Lowers PT on Enovis Corporation (ENOV) to $57 From $65, Keeps a Buy Rating - MSN
DENTSPLY SIRONA, Replimune Group, and Enovis Analysts Maintain Neutral Ratings - AInvest
Moderna, Teleflex, Envista, Enovis, and UnitedHealth Shares Are Soaring, What You Need To Know - TradingView
Full technical analysis of Enovis Corporation stockTop Stock Picks with Forecast Accuracy - Newser
Forecasting Enovis Corporation price range with options dataMomentum Stocks with Breakout Potential - Newser
Enovis to Present at Three Upcoming Investor Conferences - MSN
Is Enovis Corporation meeting your algorithmic filter criteriaEntry Zone Watchlist With Momentum Focus - Newser
How to recover losses in Enovis Corporation stockMulti-Bagger Detection with Trend Tools - Newser
Will Enovis Corporation outperform the marketRisk Aware Trading Ideas with Alert Levels - Newser
Enovis Corporation Reports Strong Growth Amid Challenges - TipRanks
Enovis Corp's December 2026 Options Begin Trading - AInvest
Quantitative breakdown of Enovis Corporation recent moveFree AI Powered High Return Stock Calls - Newser
Using Python tools to backtest Enovis Corporation strategiesFree Swing Trading Plan With Smart Signals - Newser
How to interpret RSI for Enovis Corporation stockFast Entry Strategy with Price Prediction - Newser
Order flow analysis tools used on Enovis CorporationFree Real Market Momentum Signal Generator - Newser
Enovis raises 2025 revenue guidance to $2.275B amid CEO transition and product momentum - MSN
What institutions are buying Enovis Corporation stock nowWeekly Price Target Forecast and Alerts - Newser
What does recent volatility data suggest for Enovis CorporationInvestment Life Cycle Planning Summary - Newser
Tick level data insight on Enovis Corporation volatilityInvestment Roadmap for High Potential Stocks - Newser
Needham & Company LLC Cuts Enovis (NYSE:ENOV) Price Target to $49.00 - Defense World
Enovis Delivers 7% Sales Growth in Q2, Raises Full-Year Outlook - MSN
Earnings Release: Here's Why Analysts Cut Their Enovis Corporation (NYSE:ENOV) Price Target To US$53.40 - Yahoo Finance
Enovis Corporation (NYSE:ENOV) Q2 2025 Earnings Call Transcript - MSN
Wells Fargo Maintains Enovis Corp(ENOV.US) With Buy Rating, Cuts Target Price to $41 - 富途牛牛
Does Enovis Corporation stock pay reliable dividendsFree Growth Based Investment Plan Guidance - Newser
Enovis Corporation Reports Q2 2025 Financial Results - The Globe and Mail
Enovis 2025 Q2 Earnings Net Loss Widens Sharply - AInvest
Enovis' Q2 2025: Unraveling Contradictions in Recon Growth, Market Dynamics, and Financial Strategy - AInvest
Canaccord Genuity Adjusts Price Target for Enovis (ENOV) to $58. - GuruFocus
Enovis: UBS maintains Buy rating, lowers PT to $57 from $65. - AInvest
Enovis to Attend Key Investor Conferences in August and September - AInvest
Enovis (ENOV) Raises Revenue Guidance but Net Loss Widens Could Profitability Take Priority Next? - simplywall.st
Enovis Corp Inc. (ENOV) Price Performance and Its Relation to the Tech Industry - investchronicle.com
Enovis' Strategic Investor Engagement and Institutional Sentiment Shifts: A Blueprint for Medical Tech Resilience - AInvest
Enovis to Participate in Upcoming Investor Conferences - The Manila Times
UBS Adjusts Enovis Price Target to $57 From $65, Maintains Buy Rating - MarketScreener
Canaccord Genuity lowers Enovis stock price target to $58 on tariff impacts - Investing.com Nigeria
Enovis Corporation (ENOV): Navigating Tariffs and Innovation to Cement Long-Term Resilience - AInvest
Enovis Raises 2025 Revenue Guidance to $2.275B Amid CEO Transition and Product Momentum - AInvest
Enovis Corp (ENOV) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Updated Guidance By GuruFocus - Investing.com Canada
Enovis Corp (ENOV) Q2 2025 Earnings Call Highlights: Strong Reve - GuruFocus
Decoding Enovis Corp (ENOV): A Strategic SWOT Insight - GuruFocus
Enovis (ENOV) Beats Q2 Earnings and Revenue Estimates - sharewise.com
Why Enovis Corporation stock attracts strong analyst attentionLong-Term Growth Trend Summary With Confidence - Newser
Needham Maintains Enovis Corp(ENOV.US) With Buy Rating, Cuts Target Price to $49 - 富途牛牛
Needham lowers Enovis stock price target to $49 on peer multiple contraction - Investing.com Canada
Enovis' Q2 2025 Earnings Outperformance and Strategic Momentum: A Re-Rating in the Making? - AInvest
Enovis Exceeds Q2 Sales Estimates, Stock Jumps 10.3% - AInvest
Finanzdaten der Enovis Corp-Aktie (ENOV)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.31%
1.36%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):